This progressive program is a vital tool that will allow our partners to help clients of their advisors, producers and agents should they suffer the unfortunate diagnosis of cancer. As our partners have come to expect, this is another innovative step we take in order to provide the most advanced tools and technology… – William Shelow, President & CEO, LifeMark Partners
Cancer unfortunately strikes us all – whether it be directly, a family member, friend or colleague. Offering Cancer Guardian provides affordable access to comprehensive cancer support to clients through our agents and brokers. – Scott R. Perry, CEO of AmeriLife
…I am extremely grateful and comforte“We are continually committed to finding new innovative solutions for our clients. Cancer Guardian is a program that we were pleased to offer every client. It gives our clients increased peace of mind and assurance should cancer unfortunately strike.” – Daniel L. Gray, Chairman & CEO of Providenced to have them on my team as they bring a calmness to the roller coaster of emotions during this time.
The odds are sobering. Cancer is presently the 2nd leading cause of death claims, and Americans born today have a 50% risk of being diagnosed with cancer during their lifetime.(1) Most will be unprepared to navigate the complexities of health care systems to ensure the best treatment options for positive outcomes. Cancer Guardian has been developed to address the complexities of navigating the cancer journey to support longer, healthier lives.
Cancer is a complex genetic disease. Cancer Guardian provides both hereditary cancer screening to help prevent cancer, and comprehensive genomic profiling if diagnosed with cancer. Studies have shown that early detection contributes to improved survival rates. In breast cancer, early detection drives a 4x improvement in five-year survival rates.(15)
In a recent survey, 47% of cancer patients/caregivers indicated that there was “no knowledgeable advocate to help” in finding an effective treatment or solution.(16) Cancer Guardian provides dedicated Cancer Support Specialists to provide support and resources through each step of the cancer journey for improved outcomes.
Cancer Guardian solves the problem of awareness, access and affordability to services that can help improve prevention and survival. It democratizes cancer care by providing members with the advanced DNA testing and support services typically limited to those with the means and the connections to access.
Offer Policy Holders Affordable
Comprehensive Cancer Support.
1. Lifetime Risk of Developing or Dying from Cancer Basic Facts. American Cancer Society, 2019.
2. Wamberg Genomic Advisors, Cancer Survey of 204 cancer patients and nonprofessional advocates. Survey Sampling International (SSI), 2018.
3. Unger, Joseph M., et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician and Patient Barriers to Cancer Clinical Trial Participation. JNCI J NATL Cancer Institute, 2019.
4. Family Reach. Annual Report 2016. Family Reach Foundation https://familyreachorg/wp-content/uploads/
2017/05/ frf_2016_annual_report_compressedpdf Accessed July 30, 2017.
5. CancerCare. Cancer Care Patient Access and Engagement Report. New York: CancerCare. 2016.
6. Manchanda, Ranjit, et al. Population based germline testing for primary cancer prevention. Oncotarget, 2018, Vol. 9 (No. 69), pp: 33062-33063
7. Waszak, Przemyslaw M. et al. The Spread of Medical Fake News in Social Media. Health Policy & Technology Review, Elsevier, 2018.
8. Stephen S. Raab, Dana M. Grzybicki, CA Cancer J. Clin. 2010 May-Jun,60(3): 139-65
9. Raab, Stephen S. MD, et al. Quality in Cancer Diagnosis. Cancer J. Clinical 2010
10. J. Unger, et al., Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician Barriers to Cancer Clinical Trial Participation, JNCI J Natl Cancer Inst 2019
11. The State of Cancer Care in America, 2014: A report by the American Society of Clinical Oncology. Journal of Oncology Practice, 2014; 10(2):120-122
12. Sun Life Stop-Loss Report, 2019. https://sunlife.showpad.com/share/
7SzmNmJJs1a6msorM0DZA
14. Measuring Health-Related Productivity Loss. https://ww.liebertpubl.com/doi/pdf/10.3322/caac.20068.
16. Wamberg Genomic Advisors Cancer Survey of 204 cancer patients and nonprofessional advocates fielded by Survey Sampling International (SSI), 2018. Available at: https://www.managedhealthcareexecutive.com/leukemia-and-lymphoma/
most-troubling-part-cancer-treatment-patients
